ctrain.wustl.edu

880 views
794 views

Published on

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
880
On SlideShare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

ctrain.wustl.edu

  1. 1. Samuel A. Wickline, M.D. Date: February 8, 2008 Personal Information Sex: Male Date of Birth: October 23, 1952 Place: Huntington, West Virginia Marital Status: Married to Karen M. Wickline, M.D., Associate Professor of Pediatrics and Neonatology, Children’s Hospital, Washington University School of Medicine Citizenship USA Current Address Office: Cardiovascular Division; Washington University School of Medicine; 660 South Euclid Avenue; St. Louis, MO 63110; Telephone: 314-454-8811; Email: saw@howdy.wustl.edu Home: 11211 Pointe Court; St. Louis, MO 63127; Telephone: 314-842-2300 Present Positions Professor of Medicine, Washington University School of Medicine Professor of Physics, Washington University Professor of Biomedical Engineering, Washington University Professor of Cell Biology and Physiology, Washington University Director, Washington University Consortium for Translational Research in Advanced Imaging and Nanomedicine (C-TRAIN) Director, Siteman Center For Cancer Nanotechnology Excellence Executive Faculty, Institute of Biological and Medical Engineering Co-Director of Cardiovascular Engineering Graduate Training Program, Biomedical Engineering Department, Washington University Education Undergraduate: Pomona College; Claremont, California (1970-74) BA: Philosophy Graduate: University of Hawaii School of Medicine; Honolulu, Hawaii (1976-1980) 1
  2. 2. Academic Positions/Employment 1974-1976: Research Associate, Cardiovascular Research Laboratory, Queens Hospital and John A. Burns School of Medicine; Honolulu, Hawaii 1980-83: Internship and Residency in Internal Medicine: Barnes Hospital; Washington University School of Medicine; St. Louis, MO 1983-87: Clinical and Research Fellowships in Cardiology: Washington University School of Medicine; Barnes Hospital; St. Louis, MO (Research Fellow 1983-85) 1987: Assistant Professor of Medicine Washington University School of Medicine Barnes Hospital; St. Louis, MO 1988: Clinician-Scientist of the American Heart Association 1990: Assistant Professor of Physics Washington University, Department of Physics; St. Louis, MO 1992: Attending Cardiologist and Director of Echocardiography The Jewish Hospital at Washington University; St. Louis, MO 1993: Established Investigator of the American Heart Association 1993: Associate Professor of Medicine Washington University School of Medicine 1993-97: Chief of Cardiology, Jewish Hospital Washington University School of Medicine 1994: Associate Professor of Physics Washington University, Department of Physics; St. Louis, MO 1996: Co-Director of Cardiovascular Division, Washington University School of Medicine and Barnes-Jewish Hospital 2
  3. 3. 1996: Co-Director of Washington University Cardiovascular Engineering Program and Member of Executive Council, Institute of Biological and Medical Engineering, Washington University, School of Engineering and Applied Sciences 1997: Professor of Medicine Washington University School of Medicine 1997: Professor of Physics and of Biomedical Engineering Washington University School of Medicine 3
  4. 4. 2003: Professor of Cell Biology and Physiology Division of Biology and Biomedical Sciences Washington University School of Medicine University and Hospital Appointments and Committees Director, Consortium for Translational Research in Advanced Imaging and Nanomedicine (C-TRAIN) Director, Siteman Center For Cancer Nanotechnology Excellence Co-Director, Cardiovascular Engineering Graduate Program, Biomedical Engineering Member, Executive Board of the Institute of Biological and Medical Engineering Member, Washington University Center for Materials Innovation Member, Program in Computational Biology, Division of Biology and Biological Sciences Mentor, Program Committee on Imaging Sciences Medical License and Board Certification Medical License (R7B93), State of Missouri, 1983 Diplomate of the National Board of Medicine I, II, and III Diplomate of the American Board of Internal Medicine, 1984 Diplomate of the American Board of Internal Medicine, Cardiology, 1988 Honors and Awards 1) B.A. degree: Cum Laude; Pomona College 2) Lange Award for Outstanding Student sophomore, junior, and senior years; John A. Burns School of Medicine; Honolulu, Hawaii 3) First place awardee: University of Hawaii Biomedical Science Symposium (1977) for presentation of "Vectorcardiographic Infarct Sizing in Baboons" 4) Alpha Omega Alpha, 1979 5) Knowlton "Incentive For Excellence" Award, Internal Medicine Program, Washington University School of Medicine, 1986 6 6) Clinician-Scientist Award, American Heart Association, 1988-93 7) Established Investigator Award, American Heart Association, 1993-1998 8) Member, American Society of Clinical Investigation (Elected May 1995) 9) Elected to Board of Directors, Society for Cardiovascular Magnetic Resonance, 2000-2004 10) Elected Councilor to Society of Molecular Imaging (2004-2007) 11) Fellow of the American College of Cardiology 12) Fellow of the American Heart Association 4
  5. 5. 13) 2006 Reneman Laureate, University of Maastricht and Cardiovascular Research Institute of Maastricht Review/Editorial/Other Responsibilities Editorial Board: Journal of the Society of Cardiac Magnetic Resonance, Journal of Molecular Imaging, Current Cardiology Reviews 5
  6. 6. Reviewer for Journal of Clinical Investigation, Circulation, American Heart Journal, Coronary Artery Disease, Circulation Research, Atherosclerosis, Arteriosclerosis and Thrombosis, Hypertension, Journal of the American College of Cardiology, Ultrasound in Medicine and Biology, IEEE Ultrasonics Ferroelectrics and Frequency Control, Journal of Thoracic and Cardiovascular Surgery Standing Member NIH Study Section in Diagnostic Radiology, 1996-2000 Annual Scientific Program Chair Society Cardiovascular Magnetic Resonance, 1998 and 1999 Member NHLBI Special Emphasis Panel on Heart and Vascular Diseases, 1997 Member of NHLBI "SPARK-2" Working Group, Claude Lenfant, NHLBI, Director, January 2003 Member NHLBI Nanotechnology Working Group, February 2003 Member NIH Roadmap Working Group: "High-Risk Research", June 2003 NCI Nanotechnology Working Group, January 2004 Member Scientific Program Committee International Society of Magnetic Resonance in Medicine (ISMRM), 2004-2006 Scientific Advisory Board Member, Rice University Center for Biological Engineering Nanotechnology, 2004-2006 NHLBI Strategic Planning Program, Executive Committee member (Betsy Nabel, Chair), 2006-2007 NIH Roadmap Planning Program Member (Elias Zerhouni, Chair), 2006-2007 Professional Societies and Organizations Fellow, American College of Cardiology Fellow, American Heart Association American Federation for Clinical Research American Heart Association, Councils on Radiology and Clinical Cardiology American Institute of Ultrasound in Medicine Acoustical Society of America IEEE Society of Ultrasonics, Ferroelectrics, and Frequency Control Founding Member, Society of Cardiovascular Magnetic Resonance Imaging Society of Molecular Imaging Selected Major Invited National/International Academic Lectures since 1995 1995 Plenary Session Co-Chairman and Invited Speaker at June 1995 International Acoustical Society, (Trondheim, Norway) 1995 Plenary Session Invited Speaker for Acoustical Society of America 126th International Meeting, (St. Louis, MO) 1995 Borun Visiting Professor, UCLA, November 11, 1995 (Los Angeles, CA) 1996 Invited International Speaker at Japanese Circulation Society Meeting (60th Annual Meeting), “Site Targeted Ultrasound Contrast”, March 21, 1996 (Osaka, Japan) 6
  7. 7. 1996 Co-Organizer Cardiovascular Science and Technology Conference (NIH Affiliated), Session Chairman and Invited Speaker, May 2-3, 1996 (Washington, D.C.) 1996 Plenary Session Invited Speaker for 1996 QNDE (Quantitative Nondestructive Evaluation) National Meeting, August 1996, Portland, Maine 1996 Plenary Session Speaker, Co-Organizer, and Co-Chairman of First NIH “Working Group” Conference on Cardiovascular MRI, September 1996 (Bethesda, MD) 1996 Plenary Session Invited Speaker for Japanese Society for Magnetic Resonance in Medicine, September 11-13, 1996 (Tokyo, Japan) 1997 Invited Speaker to “Interdisciplinary Workshop in New Developments in Noninvasive Cardiac Imaging”, sponsored by European Society of Cardiology, May 1997 (Alpbach, Austria) 1997 Invited Speaker to American Society for Artificial Internal Organs, “Imaging Infections in Implanted Devices”, May 1997 (Atlanta, GA) 1997 Plenary Session Speaker for QNDE (Quantitative Nondestructive Evaluation) International Meeting, “ Cardiovascular MRI”, July 29, 1997 (San Diego, CA) 1997 Invited Speaker to NHLBI Workshop on “Treatment and Diagnosis of Cardiac Maladaptive Remodeling”, September 15-16, 1997, NIH (Bethesda, MD) 1997 Co-Chairman of NHLBI Special Emphasis Panel on “Thrombosis and Infection in Implanted Medical Devices”, October 1997, Natcher Auditorium, NIH (Bethesda, MD) 1998 Invited Panelist to NIH Symposium “Bioengineering: Building the Future of Biology and Medicine”, February 27-28, 1998 (Bethesda, MD) 1999 Program Chairman for Society for Cardiovascular MR Annual Scientific Session, January 1999 (Atlanta, GA) 1999 Invited Speaker to Society for Cardiovascular Magnetic Resonance Symposium, The Role of MRI in Cardiology, on “Integrating CMR in Cardiology”, March 6, 1999 (New Orleans, LA) 1999 Invited Speaker to American College of Cardiology 48th Annual Scientific Session, New Developments in Contrast Echo, on “Targeted Agents for Enhanced Therapy”, March 9, 1999 (New Orleans, LA) 1999 Invited Speaker to “Interdisciplinary Workshop in New Developments in Noninvasive Cardiac Imaging”, sponsored by European Society of Cardiology, May 1999 (Alpbach, Austria) 1999 Invited Plenary Session Speaker to NIH BECON Symposium, Biomedical Imaging: Visualizing the Future of Biology and Medicine, on “Clinical Prospects for Imaging and Managing Angiogenesis in Cancer and Atherosclerosis”, June 25, 1999 (Bethesda, MD) 1999 Invited Speaker to National Cancer Institute sponsored Symposium, Imaging in 2020 Conference, on “Molecular and cellular imaging of the cardiovascular system”, September 1999 (Jackson Hole, WY) 7
  8. 8. 2000 Program Chairman and Invited Speaker for Society for Cardiovascular MR Annual Scientific Session, January 2000 (Atlanta, GA) 2000 Invited Speaker at the 2000 “Metals in Biology” Gordon Conference on “Molecular and Cellular Imaging of the Cardiovascular System”, January 2000 (Ventura, CA) 2000 Invited Panelist and Speaker to the National Cancer Institute sponsored symposium, “Angiogenesis Imaging Methodology: Role of Imaging in Clinical Trials of Anti-angiogenic Therapy in Oncology” (“AIM for Clinical Trials”), February 2000 (Lake Tahoe, NV) 2000 Invited Speaker and Session Chair at the 2000 Meeting of the World Congress on Medical Physics and Biomedical Engineering, July 2000 (Chicago, IL) 2000 Invited Speaker at National Cancer Institute, Second National Forum on Biomedical Imaging in Oncology: “Overview of angiogenesis: Ultrasound”, September 2000 (Alexandria, VA) 2000 Invited Speaker at Biomedical Engineering 2000 Meeting on “High frequency myocardial tissue characterization”, October 2000 (Seattle, WA) 8
  9. 9. 2000 Invited Plenary Speaker at the IEEE-UFFC Ultrasonics Symposium on “Targeted contrast agents for molecular diagnosis”, October 2000 (San Juan, PR) 2000 Invited Speaker at AHA/SCMR on “How to get started in Cardiac MR”, November 2000 (New Orleans, LA) 2001 Invited Speaker at University of Missouri-Columbia’s Cardiovascular Day on “Imaging molecular epitopes responsible for angiogenesis with novel targeted contrast agents”, February 2001 (Columbia, MO) 2001 Invited Speaker at American Institutes for Ultrasound in Medicine on “Ultrasonic molecular imaging and intervention”, March 2001 (Orlando, FL) 2001 Invited Plenary Speaker at International Society of Magnetic Resonance in Medicine (ISMRM) on “Molecular imaging with targeted contrast agents”, April 2001 (Glasgow, Scotland) 2001 Invited Speaker at the Contrast Media Research 2001 Meeting on “Liquid perfluorocarbon nanoparticles: a “new” class of blood pool contrast agents for ultrasound that exhibit marked and prolonged blood contrast enhancements in vivo with Power Doppler Harmonic (PDH) imaging”, October 2001 (Capri, Italy) 2002 Invited Speaker at the SCMR 5th Annual Scientific Sessions on “Molecular targets for detection of atherosclerosis”, January 2002 (Orlando, FL) 2002 Invited Plenary Speaker at the 2002 Annual Scientific Sessions American College of Cardiology on “Molecular Imaging”, March 2002 (Atlanta, GA) 2002 Invited Plenary Speaker at the 2002 Annual Scientific Sessions American College of Cardiology at Anatomic and Physiological Lesion Assessment: Investigational and Therapeutic Session on "MRI Applications to Coronary Artery Evaluation", March 2002 (Atlanta, GA) 2002 Invited Plenary Speaker at the 2002 Annual Scientific Sessions American College of Cardiology at Magnetic Resonance Imaging for Coronary Imaging and Therapy Session, March 2002 (Atlanta, GA) 2002 Invited Plenary Speaker at the 25th Annual Conference for Ultrasonics in Biophysics and Bioengineering's Session on Imaging with Contrast Agents II, May 2002 (Allerton Park, IL) 2002 Plenary Speaker at the Society of Molecular Imaging Meeting on "Molecular Imaging with nanoparticles", August 2002 (Boston, MA) 2002 Invited Speaker at Board of External Advisors (BEA) meeting of the NHLBI, September 2002 (Washington, DC) 2002 Invited Speaker at the 3rd Annual BioMEMs & Biomedical Nanotechnology World 2002 meeting, September 2002, (Florida) 2002 Invited Speaker at AHA on "Thrombus-Avid MR Contrast Agents in Molecular Basis for Cardiac Imaging", November 2002 (Orlando, FL) 2003 Invited Speaker at the SCMR Annual Scientific Sessions on "CMR in Clinical Decision- 9
  10. 10. Making", February 2003 (Lake Buena Vista, FL) 2003 Invited Speaker at the 52nd Annual Scientific Session of the American College of Cardiology on "A Primer of Magnetic Resonance and Computed Tomography for the Practitioner: Certification/Accreditation/Reimbursement", March 2003 (Chicago, IL) 2003 Invited Lecturer at IEEE-UFFC Conference on "Transducer Design, High Frequency Ultrasound for Molecular Imaging", March 2003 (Los Angeles, CA) 2003 Speaker at International Society of Magnetic Resonance in Medicine Molecular Imaging Symposium, "Ultrasound Molecular Imaging", June 2003 (Bordeaux, France) 2003 Scientific Program Committee and Session Moderator for Society for Molecular Imaging, August 2003 (San Francisco, CA) 2003 Invited Speaker at the European Society of Cardiology's Congress 2003 on "Targeting Thrombi and Plaques", August 2003 (Vienna, Austria) 2003 Speaker and Moderator: Gordon Research Conference on "Assisted Circulation", September 2003 (Big Sky, MT) 2003 Keynote Speaker: UCSD Biomedical Engineering Scientific Symposium on "Molecular Imaging", November 2003 (San Diego, CA) 2004 Invited Speaker at the SCMR Annual Scientific Meeting "CMR in the United States: What does it take?", February 2004 (Barcelona, Spain) 2004 Keynote Address: National Cancer Institute Symposium "Nanotechnology and Cancer Imaging", Fred Hutchinson Cancer Institute, March 2004 (Seattle, WA) 2004 Invited Speaker at the 3rd Scientific Meeting of the TMJ Association’s Advancing Diagnostic Approaches for TMJ Disorders on “Molecular Imaging with Targeted Nanoparticles”, May 2004 (Bethesda, MD) 2004 Invited Speaker at International Society of Magnetic Resonance in Medicine on "CMR and Cardiovascular Disease", May 2004 (Kyoto, Japan) 2004 Invited Speaker at International Vulnerable Plaque Society 2nd Annual Meeting on "Molecular Imaging of Vulnerable Plaque", June 2004 (Taormina, Italy) 2004 Invited Speaker at Annual Scientific Meeting American Institute of Ultrasound in Medicine on "Ultrasound Contrast Agents for Molecular Imaging", June 2004 (Phoenix, AZ) 2004 Invited Speaker at the BioMEMS and NANOtech World 2004 Conference, August 2004 (Washington, DC) 2004 Invited Plenary Speaker to European Society of Cardiology: "Cardiovascular Molecular Imaging", August 2004 (Munich, Germany) 2004 Invited Speaker at the 8th Annual Scientific Meeting of the Heart Failure Society of America, on “Targeted Imaging and Therapeutics”, September 2004 (Toronto, Canada) 2004 Invited Speaker at the 4th International Ultrasonic Biomedical Microscanning Conference on “Targeted Contrast Agents”, September 2004 (Arden House, NY) 10
  11. 11. 2004 Invited Speaker at the 2nd Annual National Academies Keck Futures Initiative “Designing Nanostructures” Pre-Conference, September 2004 (Washington, DC) 2004 Invited Speaker at the Transcatheter Cardiovascular Therapeutics (TCT) 2004 Conference, September 2004 (Washington, DC) 2004 Invited Speaker, Barbara Davis Diabetes Foundation Scientific Session & Benefit, “Molecular Imaging”, October 2004 (Beverly Hills, CA) 2004 Invited Speaker at the 19th Annual Advances in Contrast Ultrasound/Bubble Course 2004, November 2004 (Chicago, IL) 2005 Invited Speaker at Society for Cardiovascular Magnetic Resonance 8th Annual Scientific Sessions 2005, “Molecular Imaging by CMR”, January 2005 (San Francisco, CA) 2005 Invited Speaker at the European Congress of Radiology 2005 on “Targeted MR contrast agents”, March 2005 (Vienna, Austria) 2005 Invited Speaker at the 69th Annual Scientific Meeting of the Japanese Circulation Society, “Molecular Imaging and Targeted Therapeutics”, March 2005 (Yokohama, Japan) 2005 Invited Speaker, International Society of Magnetic Resonance in Medicine, “MRI and Molecular Imaging”, May 2005 (Miami, FL) 2005 Invited Speaker, German Heart Institute Berlin, May 2005 (Berlin, Germany) 2005 Invited Speaker, 3rd Vulnerable Plaque Meeting, June, 2005 (Capri, Italy) 2005 Invited Speaker, Congressional Biomedical Research Caucus, “What is Nanotechnology and How Might it be Useful in Clinical Practice? An Example of Heart Disease”, July 2005, (Washington, DC) 2005 Invited Speaker, 53rd Scientific Sessions of the Japanese College of Cardiology, “Advance of Intervention with Imaging Systems”, September 2005 (Osaka, Japan) 2005 Invited Speaker, XXVI National Congress of the Italian Society of Invasive Cardiology (GISE), “Seeing within: Molecular imaging of the vulnerable plaque”, September 2005, (Genoa, Italy) 2005 Invited Speaker, AACR/NCI/EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, “Molecular Imaging and Targeted Therapeutics with Perfluorocarbon Nanoparticles”, November 2005 (Philadelphia, PA) 2006 Invited Speaker, Preconference Society for Cardiovascular Magnetic Resonance 9th Annual Scientific Sessions, “Valvular function/flow: MR challenges echocardiography”, January 2006 (Miami, FL) 2006 Plenary Speaker, Japanese Ministry of Health Symposium, “Molecular Medicine and the Future of Medicine”, February 17, 2006 (Tokyo, Japan) 11
  12. 12. 2006 Invited Speaker, American College of Cardiology Annual Scientific Sessions, “Aortic and mitral valve dysfunction and shunts by MRI: Why quantification matters”, March 12, 2006 (Atlanta, GA) 2006 Invited Speaker, Fourth International Symposium on Targeted Anticancer Therapeutics (TAT), March 18, 2006 (Amsterdam, Netherlands) 2006 Invited Speaker, Transcatheter Therapeutics Symposium, “Molecular Imaging: Magnetic resonance nanoparticles for enhanced imaging of vulnerable plaque and developing collaterals”, April 6, 2006 (Washington, DC) 2006 Keynote Address, Ohio Academy of Science Annual Scientific Sessions, “Targeted nanosystems for diagnosis and therapy,” April 22, 2006 (Dayton, OH) 2006 Invited speaker, University of Illinois Urbana-Champaign Annual Nanotechnology Workshop, “Molecular Imaging and targeted therapy of cardiovascular disease and cancer”, May 2006 (Urbana Champaign, IL) 2006 Invited Speaker, EuroPCR 2006, “Molecular imaging of cardiovascular disease”, May 18, 2006 (Paris, France) 2006 Plenary Speaker, Washington University Symposium on Advances in Targeted Therapy, “Smart nanoparticles for molecular imaging and targeted therapy of cancer”, May 2006 (St. Louis, MO) 2006 Invited Speaker, Deutsches Herz Centrum Symposium on Molecular Imaging, June 23, 2006 (Berlin, Germany) 2006 Plenary Speaker, First IDEA League Summer School: Biotechnology and Bioengineering Applications in Medicine, September 21, 2006 (Ascona, Switzerland) 2006 Plenary Speaker, Materials, Medicine, and Nanotechnology Summit: Plenary Session IV- Nanotechnology, October 2006 (Cleveland, OH) 2006 Invited Speaker, Cambridge Healthtech Institute’s Targeted Nanodelivery, October 2006 (Baltimore, MD) 2006 Invited Speaker, 2006 Cancer Patient Education Network (CPEN) 2006; Annual Conference, October 2006 (St. Louis, MO) 2006 Invited Speaker, American Heart Association Scientific Sessions 2006, “Molecular imaging of vulnerable plaques and developing collaterals,” November 2006 (Chicago IL) 2006 Invited Speaker, 2006, Association of Molecular Pathology Annual Meeting, “Ligand targeted nanoparticles for cancer diagnosis and therapy”, November 2006 (Orlando, Florida) 2006 Invited Speaker, Global Cardiovascular Interventions XVIIth International Course, “Magnetic resonance imaging for detection of unstable coronary plaque”, November 2006 (Frankfurt, Germany) 12
  13. 13. 2006 Reneman Laureate Lecturer, CARIM Symposium (Cardiovascular Research Institute of Maastricht), “Molecular Imaging and Drug Delivery for Cancer and Cardiovascular Disease With Targeted Nanoparticles”, November 29, 2006 (Maastricht, Netherlands) 2007 Invited Speaker, 71st Annual Scientific Meeting of the Japanese Circulation Society (JCS), March 2007 (Kobe, Japan) 2007 Invited speaker, Symposia Biomedica, “Nanotechnology for molecular imaging and targeted therapeutics”, March 21, 2007 (Aachen, Germany) 2007 Invited Speaker, National Science Teachers Association Annual Conference, March 25, 2007 (St. Louis, MO) 2007 Invited speaker, American College of Cardiology Annual Scientific Sessions, “CMR in valve disease”, March 25, 2007 (New Orleans, LA) 2007 Plenary speaker, American Society of Clinical Oncology Annual Scientific Sessions, May 3, 2007 (Chicago, IL) 2007 Invited speaker, International Society of Magnetic Resonance in Medicine Annual Scientific Sessions, “Gadolinium nanoparticle contrast agents” May 24, 2007 (Berlin, Germany) 2007 Keynote Lecture, American Chemical Society 234th Annual Scientific Meeting, Nanostructured Fluorocarbons. Smart modules for self assembly processes and synthetic Protocols, Aug 19-23, 2007 (Boston, MA) 2007 Keynote Address, William Beaumont Hospital’s 16th Annual Symposium on Molecular Pathology, DNA Technology in the Clinical Laboratory, Targeted nanosystems for molecular imaging and personalized therapeutics, Sep 27, 2007 (Troy, MI) 2007 Special Lecture, 19th Transcatheter Cardiovascular Therapeutics Meeting, Nanoparticles for molecular imaging and targeted therapeutics: Application for vulnerable plaque detection and treatment, Oct 2007 (Washington, DC) 2007 Invited speaker, Nanotechnology in Biology & Medicine, Nanoemulsions for multimodal molecular imaging and targeted therapeutics, Nov 2007 (Charlotte, NC) 2008 Invited speaker, 11th Annual SCMR Scientific Sessions, Gd-Labeled Nanoparticles for Moelcular MRI and Fluorine Imaging: An Alternative Approach to Mlecular MRI, Jan 2008 (Los Angeles, CA) Consulting/Corporate Relationships Consultant: Philips Medical Systems, Dow Chemical, and Bristol-Myers Squibb Founder: Kereos, Inc., St. Louis, MO; Board of Directors, and Chairman of S.A.B. Founder: PixelEXX, Inc., St. Louis, MO; Board of Directors, and acting Co-President Patents (US filings only: partial listing; disclosures not included) 1) “Avidin-biotin conjugated emulsions as a site specific binding system” (issued 11/25/97, #5,569,907) 13
  14. 14. 2) “Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system” (issued 7/14/98, #5,780,010) 3) “Site specific binding systems, imaging compositions, and methods” (issued, 11/23/99, #5,989,520) 4) “Site specific binding system, imaging compositions and methods” (issued 9/28/99, #5,958,371) 5) “Ligand-targeted emulsions carrying bioactive agents” (issued 1/13/04, #6,676,963) 6) “Site specific binding system, nuclear imaging compositions, and methods” (issued 4/15/03, #6,548,046) 7) “Enhanced ultrasound detection with temperature-dependent contrast agents” (issued 2/20/07, #7,179,449) 8) "Paramagnetic particles that provide improved relaxivity" (issued 3/22/05, #6,869,591) 9) "Site-Specific Binding System, Imaging Compositions and Methods" (issued 11/23/04, #6,821,506) 10) “ECG triggered MR imaging method and apparatus” (issued February, 1999, #W09904688) 11) “Methods for targeted drug delivery” (issued 3/6/07, #7,186,399) 12) “Paramagnetic particles that provide improved relaxivity” (issued 6/26/07, #7,235,227) 13) “Blood clot-targeted nanoparticles” (issued 5/22/07, #7,220,401) 14) "Method and Apparatus for Intracorporeal Medical Imaging Using a Self-Tuned Coil" (Issued) 15) "Method and Apparatus for Intracorporeal Medical Imaging Using Self-Tuned Coils" (Docket 66435/40272, filed 6/5/03) 16) “Integrin targeted imaging agents” issued 8/14/07, #7,255,875) 17) “Targeted nanoparticles” (#60/400,452, filed 7/31/02) 18) “Chelating agents with lipophilic carriers” (issued 10/9/07, #7,279,150) 19) “Relaxivity of paramagnetic nanoparticles for molecular imaging depends on chelate conformation” (filed 3/26/02, 60/368,100) 20) “Emulsion particles for imaging and therapy and methods of use thereof” (filed 08/08/03, 60/493,492) 21) “Enhanced drug delivery” (filed 11/19/03, 60/523,833) 22) “Improved efficacy and safety of targeted particulate agents with decoy systems” (filed 2/10/04, 60/543,761) 23) “Emulsion particles for imaging and therapy and methods of use thereof” (filed 8/6/04, #10/913,846) 24) “System and methods for ultrasonic characterization of internal body conditions using information theoretic signal receivers” (filed 6/2005) 14
  15. 15. 25) “Multifunctional nanoscopy for imaging cells” (provisional filed 9/2006) 26) “Cell labeling with perfluorocarbon nanoparticles for magnetic resonance imaging and spectroscopy” (provisional filed 2/24/2006) 27) “MR coronary angiography with a fluorinated nanoparticle contrast agent 1.5T” (filed 3/4/2005) 28) “Methods to ameliorate and image angioplasty induced vascular injury” (filed 2/28/07) 29) “Cytotoxic peptides on nanoparticle carriers for therapy” (filed) 30) “Multispectral molecular imaging with fluorine-containing agents” (filed 6/14/07, #11/762,903) 31) “Lipid-encapsulated magnetic nanoparticle” (filed 10/9/07, #60/978,678) 32) “Nano-bialys particles and uses thereof” (filed 10/9/07, #60/978,679) 33) “Integrin targeted imaging agents” (filed, #1 11305,416) 34) “Targeted cell-penetrating peptides” (submitted, docket 295003007300) Current Research Support Current Governmental U54 (CA119342) National Institutes of Health, September 2005 to August 2010; Total Award $16,643,205: The Siteman Center of Cancer Nanotechnology Excellence. Principal Investigator: Samuel A. Wickline, M.D., $2,330,739 (direct), 30% effort. RO1 (HL073646) National Institutes of Health, July 2004 to June 2009; Total Award $6,357,997: Methods in molecular imaging and targeted therapeutics. Principal Investigator: Samuel A. Wickline, MD., $1,149,071/yr (direct), 35% effort N01-CO-37007 National Cancer Institute, September 2003 to September 2007; Total Award $5,097,055: Novel Technologies for Noninvasive Detection, Diagnosis and Treatment of Cancer. Principal Investigator: Gregory M. Lanza, M.D., Ph.D., $1,130,806 (direct), 5% effort. R01 (EB001704) National Institutes of Health, December 2003 to November 2008; Total Award $905,512: Molecular Imaging of Angiogenesis by MRI. Principal Investigator: Patrick Winter, Ph.D., $157,500/yr (direct), unpaid consultant. RO1 (HL78631) National Institutes of Health, September 2004 to August 2008; Total Award $1,504,116: Combined therapeutic-imaging agent for atherosclerosis. Principal Investigator: Gregory M. Lanza, M.D., Ph.D., $244,125 (direct), 10% effort. P20 (RR020643) National Institutes of Health, September 2004 to July 2007; Total Award $1,747,250: Planning Interdisciplinary Studies of the Diabetic Heart. Principal Investigator: Daniel Kelly, M.D., $373,269 (direct), 5% effort. 15
  16. 16. P50 (HL083762) National Institutes of Health, May 2006 to Mar 2011; Total Award $10,243,987: SCCOR in Metabolic Syndrome and Vascular Disease. Principal Investigator: Clay Semenkovich, M.D. Core B: Clinical Imaging Core. Principal Investigator Core B: Samuel A. Wickline, M.D. $258,087 (direct), 5% effort. Current Nongovernmental Philips Medical Systems, “Cardiovascular magnetic resonance imaging”, 2000-2009 (~$370,000/yr in personnel/equipment/service contracts) for implementation of a new Cardiac MRI program at Barnes- Jewish Hospital within the Department of Medicine, Division of Cardiology. Three PhD Engineers and Physicists are supported with these monies, as well as equipment and travel expenses. P.I.: Samuel Wickline, M.D. Total Award $10 million/5 yr. 16
  17. 17. Teaching Graduate Level Courses Coursemaster: BME 502, “Cardiovascular MRI: From Physics to Practice” Spring semester yearly Coursemaster: BME/DBBS #?? “Topics in Nanotechnology” Fall 2007 Annual Symposia Director: Washington University Cardiac MRI Training Course: "A Practical Course", March- April yearly Mentorship Current degree candidates Alex Waters, M.S. (Ph.D. BME: 2008) Neelesh Soman, M.S. (Ph.D. BME: 2008) Megan Kaneda, M.S. (Ph.D. BME: 2008) Kejia Cai, M.S. (Ph.D. BME: 2009) Lei Zhang, M.S. (Ph.D. BME: 2009) Jacob Meyerson (Ph.D. BME: 2010) Current postdoctoral Steve Baldwin, Ph.D.; Ultrasound Hua Pan, Ph.D., Nanotechnology Previous degree candidates Kathy Partlow, Ph.D. (2000-2007); UIUC post-doctoral, Urbana, IL Anne Neubauer, Ph.D. (2004-2007); Philips Medical Systems Jason Brant, M.S. (20005-2007); Medical Student, Washington University Junjie Chen, D.Sc. (2000-2004); Staff Scientist, Washington Univ. (Wickline lab) Wei Liu, D.Sc. (2000-2004); Clinical Sites Research Scientist, Philips Research USA Previous Postdoctoral Marvin Ashford, M.D. (2002-2004); Private Practice, Little Rock, AR Jina Chung, M.D. (2003-2006); Cardiologist, Los Angeles Cardiology Associates Catherine Dent, M.D. (1998-2000); Assoc Prof of Pediatrics, Univ. of Ohio, Cincinnati, OH Cuong Nguyen, M.D. (1996-1999); Practicing Physician; Los Vegas, NV Gregory Lanza, M.D. (1994-1999); Assoc Prof of Medicine and BME, Washington University Angel Lopez-Candales, M.D. (1993-1996); Assoc Prof of Cardiology, Univ. of Pittsburg, PA Angel Sharkey, M.D. (1992-1997); Assoc Prof of Pediatrics, Washington University Christopher Hall, Ph.D. Physics (1992-1996); Laboratory Director, Philips Medical Systems, 17
  18. 18. NY, NY Glenn Davison, M.D. (1992-1994); Private Practice, Chesterfield, MO Dino Recchia, M.D. (1991-1994); Private Practice, Travers City, MI Lori Bridal, Ph.D. Physics (1990-1994); Research Scientist, Paris, FR Victor Davila, M.D. (1998-2000); Prof of Medicine and Radiology, Washington University 18
  19. 19. Thesis Committee Physics: Scott Handley, Mark Holland, Brent Hoffmeister, Lori Bridal, Mark Kaufmann, Ed Verdonk, Kyle Holman, Chris Hall, Joel Moberly, Jon Marsh, Steve Baldwin, and Charles Chung BME: Andy Hall, Jon Chia, Brad Wacker, Hua Pan Computer Science: Richard Souvenier (PhD 2006) Bibliography 1. McDanal JT, Wickline SA, Suehiro GT, Thomas VE, McNamara JJ: Further studies on the significance of microaggregates in stored blood. Surg Forum. 1975; 26: 214. 2. Wickline SA, McNamara JJ: Vectorcardiographic quantification of infarct size. Surg Forum 1977; 28: 244-245. 3. Wickline SA, Soeter JR, McNamara JJ: Oxygenation of the cerebral and coronary circulation with right axillary artery perfusion during venoarterial bypass in primates. Ann Thoracic Surg 1977; 24: 560-565. 4. Wickline SA, McNamara JJ: Vectorcardiographic quantification of infarct size in baboons. Circulation 1978; 57: 910-920. 5. Ruf W, McNamara JJ, Suehiro GT, Wickline SA: Platelet trapping in myocardial infarct in baboons: Therapeutic effect of aspirin. Am J Cardiol 1980; 46: 405-412. 6. Wickline SA, Thomas LJ III, Miller JG, Sobel BE, Perez JE: The dependence of myocardial ultrasonic backscatter on contractile performance. Circulation 1985; 72: 183-192. 7. Wickline SA, Thomas LJ III, Miller JG, Sobel BE, Perez JE: A relationship between ultrasonic integrated backscatter and myocardial contractile function. J Clin Invest 1985; 76: 2151-2160. 8. Thomas LJ III, Wickline SA, Perez JE, Sobel BE, Miller JG: A real-time integrated backscatter measurement system for quantitative cardiac tissue characterization. IEEE Trans on Ultrasonics, Ferroelectrics, and Frequency Control 1986; 33: 27-32. 9. Wickline SA, Thomas LJ III, Miller JG, Sobel BE, Perez JE: Sensitive detection of the effects of reperfusion on myocardium by ultrasonic tissue characterization with integrated backscatter. Circulation 1986; 74: 389-400. 19
  20. 20. 10. Vered Z, Mohr GA, Barzilai B, Gessler CG, Wickline SA, Wear KA, Shoup TA, Weiss AN, Sobel BE, Miller JG, Perez JE: Ultrasonic integrated backscatter characterization of remote myocardial infarction in human subjects. J Am Coll Cardiol 1989; 13: 84-91. 11. Thomas LJ III, Barzilai B, Perez JE, Sobel BE, Wickline SA, Miller JG: Quantitative real-time imaging of myocardium based on ultrasonic integrated backscatter. IEEE Trans on Ultrasonics, Ferroelectrics, and Frequency Control 1989; 36: 466-470. 12. Wear KA, Milunski MR, Wickline SA, Perez JE, Sobel BE, Miller JG: Differentiation between acutely ischemic myocardium and zones of completed infarction in dogs on the basis of frequency-dependent backscatter. J Acoust Soc Am 1989; 85: 2634-2641. 13. Milunski MR, Canter CE, Wickline SA, Sobel BE, Miller JG, Perez JE: Cardiac cycle- dependent variation of integrated backscatter is not distorted by abnormal myocardial wall motion in human subjects with paradoxical septal motion. Ultrasound Med Biol 1989; 15: 311-317. 14. Milunski MR, Mohr GA, Wear KA, Sobel BE, Miller JG, Wickline SA: Early identification with ultrasonic integrated backscatter of viable but stunned myocardium in dogs. J Am Coll Cardiol 1989; 14: 462-471. 15. Milunski MR, Mohr GA, Perez JE, Vered Z, Wear KA, Gessler CJ, Sobel BE, Miller JG, Wickline SA: Ultrasonic tissue characterization with integrated backscatter. Acute myocardial ischemia, reperfusion, and stunned myocardium in patients. Circulation 1989; 80: 491-503. 16. Wear KA, Milunski MR, Wickline SA, Perez JE, Sobel BE, Miller JG: Contraction- related variation in frequency dependence of acoustic properties of canine myocardium. J Acoust Soc Am 1989; 86: 2067-2072. 17. Wickline SA, Barzilai B, Thomas LJ III, Saffitz JE: Quantification of intimal and medial thickness of human coronary arteries by acoustic microscopy. Coronary Artery Disease 1990; 1: 375-381. 18. Verdonk ED, Wickline SA, Miller JG: Quantification of the anisotropy of ultrasonic quasilongitudinal velocity in normal human and canine myocardium with comparison to anisotropy of integrated backscatter. IEEE Ultrason Symp 1990; 90CH2938-9: 1349-1352. 19. Wear KA, Milunski MR, Wickline SA, Perez JE, Sobel BE, Miller JG: The effect of frequency on the magnitude of cyclic variation of backscatter in dogs and implications for prompt 20
  21. 21. detection of acute myocardial ischemia. IEEE Trans on Ultrasonics, Ferroelectrics, and Frequency Control 1991; 38: 498-502. 20. Wickline SA, Verdonk ED, Miller JG: Three-dimensional characterization of human ventricular myofiber architecture by ultrasonic backscatter. J Clinical Invest 1991; 88: 438-446. 21. Hoffmeister BK, Wong AK, Verdonk ED, Wickline SA, Miller JG: Quantitative assessment of the directional dependence (anisotropy) for ultrasonic backscatter in human tendon. IEEE Ultrason Symp 1991; 91CH3079-1: 1127-31. 22. Wickline SA, Verdonk ED, Wong AK, Shepard RK, Miller JG: Structural remodeling of human myocardial tissue after infarction. Quantification with ultrasonic backscatter. Circulation 1992; 85: 259-268. 23. Wickline SA, Verdonk ED, Sobel BE, Miller JG: Identification of human myocardial infarction in vitro based on the frequency dependence of ultrasonic backscatter. J Acoust Soc Am 1992; 91: 3018-25. 24. Wong AK, Verdonk ED, Hoffmeister BK, Miller JG, Wickline SA: Detection of unique transmural architecture of human idiopathic cardiomyopathy by ultrasonic tissue characterization. Circulation 1992; 86: 1108-1115. 25. Shepard RK, Miller JG, Wickline SA: Quantification of atherosclerotic plaque composition in cholesterol-fed rabbits with 50 MHz acoustic microscopy. Arteriosclerosis and Thrombosis 1992; 12: 1227-1234. 26. Verdonk ED, Wickline SA, Miller JG: Anisotropy of ultrasonic velocity and elastic properties in normal human myocardium. J Acoust Soc Am 1992; 92: 3039-3050. 27. Wickline SA, Shepard RK, Recchia D, Verdonk ED, Miller JG: Quantification of ultrasonic anisotropy of scattering from myocardium in vitro and in vivo. Proc IEEE Ultrason Symp 1992; 92CH3118-7: 1083-1086. 28. Wong AK, Osborn TA, Miller JG, Wickline SA: Quantification of ventricular remodeling in the tight-skin mouse cardiomyopathy with acoustic microscopy. Ultrasound Med Biol 1993; 19: 365-374. 21
  22. 22. 29. Recchia D, Wickline SA: Ultrasonic tissue characterization of blood during stasis and thrombosis with a real-time linear-array backscatter imaging system. Coronary Artery Disease 1993; 4: 987-994. 30. Recchia D, Miller JG, Wickline SA: Quantification of ultrasonic anisotropy in normal myocardium with lateral gain compensation of two-dimensional integrated backscatter images. Ultrasound Med Biol 1993; 19: 497-505. 31. Wickline SA, Shepard RK, Daugherty A: Quantitative ultrasonic characterization of lesion composition and remodeling in atherosclerotic rabbit aorta. Arteriosclerosis and Thrombosis 1993; 13: 1543-1550. 32. Bridal SL, Recchia D, Miller JG, Wickline SA: Anisotropy of apparent integrated backscatter, signal loss and backscatter coefficient at 30 to 45 MHz in canine papillary muscle. Ultrasonic Imaging 1993; 15: 155-156. 33. Davison G, Hall CS, Scott MS, Miller JG, Wickline SA: Cellular mechanisms of captopril- induced matrix remodeling in Syrian hamster cardiomyopathy. Circulation 1994; 90: 1334-42. 34. Hoffmeister BK, Verdonk ED, Wickline SA, Miller JG: Effect of collagen on the anisotropy of quasi-longitudinal mode ultrasonic velocity in fibrous soft tissues: a comparison of fixed tendon and fixed myocardium. J Acoust Soc Am 1994; 96: 1957-64. 35. Wickline SA, Miller JG, Recchia D, Sharkey AM, Bridal L, Christy D: Beyond intravascular imaging: Quantitative ultrasonic tissue characterization of vascular pathology Proc IEEE Ultrason Symp 1994; 94CH3468-6: 1589-1597. 36. Perez JE, Miller JG, Holland MR, Wickline SA, Waggoner AD, Barzilai B, Sobel BE: Ultrasonic tissue characterization: Integrated backscatter imaging for detecting myocardial structural properties and on-line quantitation of cardiac function. Am J Card Imaging 1994; 8: 106-12. 37. Rose JH, Kaufmann MR, Wickline SA, Hall CS, Miller JG: A proposed microscopic elastic wave theory for ultrasonic backscatter from myocardial tissue. J Acoust Soc Am 1995; 97: 656-668. 38. Recchia D, Hall CS, Shepard RK, Miller JG, Wickline SA: Mechanisms of the view- dependence of ultrasonic backscatter from normal myocardium. IEEE Trans on Ultrasonics, Ferroelectrics, and Frequency Control 1995; 42: 91-98. 22
  23. 23. 39. Recchia D, Kouchoukos NT, Bosner MS, Wickline SA: Sensitive detection of abnormal aortic architecture in Marfan Syndrome with high-frequency ultrasonic tissue characterization. Circulation 1995; 91: 1036-1043 (accompanied by editorial comment). 40. Recchia D, Abendschein DR, Saffitz JE, Wickline SA: The biological behavior of balloon hyperinflation-induced arterial lesions in hypercholesterolemic pigs depends on the presence of foam cells. Arteriosclerosis Thrombosis Vasc Biol 1995; 15: 924-929. 41. Davison G, Hall CS, Miller JG, Scott M, Wickline SA: Ultrasonic tissue characterization detects captopril-induced remodeling in experimental dilated cardiomyopathy. Ultrasound Med Biol 1995; 21: 853-860. 42. Lopez-Candales A, Scott MS, Wickline SA: Cholesterol feeding modulates spatial expression of TGF-ß1 and ß2 in aortas of Watanabe rabbits. Cytokine 1995; 7: 554-561. 43. Williams EB, Halpert I, Wickline SA, Davison G, Parks WC, Rottman JN: Osteopontin expression is increased in the heritable cardiomyopathy of Syrian Hamsters. Circulation 1995; 92: 705-709. 44. Hoffmeister BK, Wong AK, Verdonk ED, Wickline SA, Miller JG: Comparison of the anisotropy of apparent integrated ultrasonic backscatter from fixed human tendon and fixed human myocardium. J Acoust Soc Am 1995; 97: 1307-1313. 45. Hoffmeister BK, Handley SM, Verdonk ED, Wickline SA, Miller JG: Estimation of the elastic stiffness coefficient C13 of fixed tendon and fixed myocardium. J Acoust Soc Am 1995; 97: 3171-3176. 46. Christy DH, Wallace KD, Lanza GM, Holland MR, Hall CS, Scott MJ, Cacheris WP, Gaffney PJ, Miller JG, Wickline SA: Quantitative intravascular ultrasound: Demonstration using a novel site targeted acoustic contrast agent. Proc IEEE Ultrason Symp 1995; 95CH35844: 1125-1128. 47. Verdonk ED, Hoffmeister BK, Wickline SA, Miller JG: Anisotropy of the slope of ultrasonic attenuation in formalin fixed human myocardium. J Acoust Soc Am 1996; 99: 3837-3843. 48. Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline SA, Parks WC: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of veriscan deposition, a proteoglycan substrate for the enzyme. Proc Nat Acad Sci 1996; 93: 9748-9753. 23
  24. 24. 49. Bridal SL, Wallace KD, Trousil RL, Wickline SA, Miller JG: Frequency dependence of acoustic backscatter from 5 to 65 MHz (0.06 < ka < 4.0) of polystyrene beads in agarose. J Acoust Soc Am 1996; 100: 1841-1848. 50. Lopez-Candales A, Holmes DR, Scott MJ, Thompson RW, Wickline SA: Effects of ultraviolet light in vascular cells in vitro and in intact atherosclerotic explants: potential role of apoptosis in vascular biology. Biochem Cell Biol 1996; 74: 333-345. 51. Abendschein D, Recchia DR, Meng YY, Oltrona L, Wickline SA, Eisenberg PR: Inhibition of thrombin attenuates stenosis after arterial injury in minipigs. J Am Coll Cardiol 1996; 28: 1849-1855. 52. Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH, Sharkey AM, Miller JG, Gaffney PJ, Wickline SA: A novel site-targeted ultrasonic contrast agent with broad biomedical application. Circulation 1996; 94: 3334-3340. 53. Hoffmeister BK, Handley SM, Wickline SA, Miller JG: Ultrasonic determination of the anisotropy of Young’s modulus of fixed tendon and fixed myocardium. J Acoust Soc Am 1996; 100: 3933-3940. 54. Lopez-Candales A, Scott MJ, Wickline SA: Different temporal and spatial distribution of TGF- beta-1 and TGF-beta-2 in rabbit vascular tissue—potential role in normal vessel growth and maturation. Cytokine 1996; 8: 675-685. 55. Lopez-Candales A, Scott MJ, Wickline SA: In vitro exposure of murine macrophages to ultraviolet light induces apoptosis. Boletin – Asociacion Medica de Puerto Rico 1996; 88: 57-62. 56. Hall CS, Verdonk ED, Wickline SA, Perez JE, Miller JG: Anisotropy of the apparent frequency dependence of backscatter in formalin fixed human myocardium. J Acoust Soc Am 1997; 101: 563-568. 57. Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR: Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon- induced arterial injury in minipigs. Circulation 1997; 96: 646-652. 58. Wickline SA: Advances in ultrasound methods for high-resolution imaging of the cardiovascular system. Trends Cardiovas Med 1997; 7: 168-174. 24
  25. 25. 59. Lanza GM, Wallace KD, Fischer SE, Christy DH, Scott MJ, Trousil RL, Cacheris WP, Miller JG, Gaffney PJ, Wickline SA: High-frequency ultrasonic detection of thrombi with a targeted contrast system. Ultrasound Med Biol 1997; 23: 863-870. 60. Lanza GM, Scott MJ, Davison G, Hall CH, Christy DH, Miller JG, Wickline SA: Angiotensin II receptor blockade in Syrian hamster (TO-2) cardiomyopathy does not affect microscopic cardiac material properties: Implications for mechanism of tissue remodeling. Cardiovas Drugs Ther 1997; 11: 521-529. 61. Davison G, Whittaker P, Wickline SA: Captopril therapy limits ventricular remodeling but does not alter myocardial collagen fiber morphology of cardiomyopathic hamsters. Cardiovasc Pathol 1997; 6: 307-313. 62. Lopez-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW: Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am J Pathol 1997; 150: 993-1007. 63. Hall CS, Lanza GM, Rose JH, Kaufmann RJ, Fuhrhop RW, Handley SH, Waters KR, Miller JG, Wickline SA: Experimental determination of phase velocity of perfluorocarbons: Applications to targeted contrast agents. Proc IEEE Ultrason Symp 1997; 97CH36118: 1605-1608. 64. Lanza GM, Lorenz CH, Fischer SE, Scott MJ, Cacheris WP, Kaufmann RJ, Gaffney PJ, Wickline SA: Enhanced detection of thrombi with a novel fibrin-targeted magnetic resonance imaging agent. Acad Radiol 1998; 5: S173-S176. 65. Hofman MBM, Adzamli K, Allen JS, Fischer SE, Brown JJ, Adams MD, Wickline SA, Lorenz, CH: Kinetics of a novel blood pool agent (MP-2269) with persistent high relaxivity of MR angiography. Acad Radiol 1998; 5: S206-S209. 66. Hofman MBM, Wickline SA, Lorenz CH: Quantification of in-plane motion of the coronary arteries during the cardiac cycle: Implications for acquisition window duration for MR flow quantification. J Magn Reson Imaging 1998; 8: 568-576. 67. Lanza GM, Trousil RL, Wallace KD, Rose JH, Hall CS, Scott MJ, Miller JG, Eisenberg PR, Gaffney PJ, Wickline SA: In vitro characterization of a novel, tissue-targeted ultrasonic contrast system with acoustic microscopy. J Acoust Soc Am 1998; 104: 3665-3672. 25
  26. 26. 68. Nagel E, Underwood R, Pennell D, Sechtem UP, Neubauer S, Wickline S, Hess OM, Schwaiger M, Fleck E: New developments in non-invasive cardiac imaging: Critical Assessment of the clinical role of cardiac magnetic resonance imaging. Eur Heart J 1998; 19: 1286-1293. 69. Fischer SE, Wickline SA, de Boer R, Johansson LOM, Lorenz CH: Technical advances towards a comprehensive cardiac magnetic resonance examination for diagnosis of coronary artery disease. IEEE Engineering in Medicine and Biology Society 1998; 20: 474-479. 70. Hall CS, Wickline SA: High frequency ultrasonic detection of protein crosslinking in myocardial tissue. Proc IEEE Ultrason Symp1998; 98CH36102: 1357-1360. 71. Hofman MBM, Henson RE, Kovacs SJ, Fischer SE, Lauffer RB, Adzamli K, DeBecker J, Wickline SA, Lorenz CH: Blood pool agent strongly improves 3D magnetic resonance coronary angiography using an inversion pre-pulse. Magn Reson Med 1999; 41: 360-367. 72. Johansson LO, Nolan MM, Taniuchi M, Fischer SE, Wickline SA, Lorenz CH: High- resolution magnetic resonance coronary angiography of the entire heart using a new blood-pool agent, NC100150 injection: Comparison with invasive x-ray angiography in pigs. J Cardiovasc Magn Res 1999; 1: 139-143. 73. Fischer SE, Wickline SA, Lorenz CH: Novel real-time R-wave detection algorithm based on the vectorcardiogram for accurate gated magnetic resonance acquisitions. Magn Reson Med 1999; 42: 361-370. 74. Marsh JN, Hall CS, Abendschein DR, Scherrer DE, Scott MJ, Fuhrhop RJ, Gaffney PJ, Wickline SA, Lanza GM: Molecular imaging using site-targeted ultrasound contrast agents. Proc IEEE Ultrason Symp 1999; 99CH37027: 1713-1716. 75. Hall CS, Scott MJ, Lanza GM, Miller JG, Wickline SA: The extracellular matrix is an important source of ultrasound backscatter from myocardium. J Acoust Soc Am 2000; 107: 612-619. 76. Hall CS, Lanza GM, Rose JH, Kaufmann RJ, Fuhrhop RW, Handley SH, Waters KR, Miller JG, Wickline SA: Experimental determination of phase velocity of perfluorocarbons: Applications to targeted contrast agents. IEEE Trans Ultrason Ferroelec Freq Contr 2000; 47: 75-84. 77. Lanza GM, Abendschein DR, Hall CS, Marsh JN, Scott MJ, Scherrer DE, Wickline SA: 26
  27. 27. Molecular imaging of stretch-induced tissue factor expression in carotid arteries with intravascular ultrasound. Invest Radiol 2000; 35: 227-234. 78. Flacke S, Setser RM, Barger P, Wickline SA, Lorenz CH: Coronary aneurysms in Kawasaki’s disease detected by magnetic resonance coronary angiography. Circulation 2000; 101: e156-e157. 79. Hall CS, Abendschein DR, Scherrer DE, Scott MJ, Marsh JN, Wickline SA, Lanza GM: Site-targeted acoustic contrast agent detects molecular expression of tissue factor after balloon angioplasty. Journal of Society of Photo-optical Instrumentation Engineers 2000; 1: 325-332. 80. Marsh JN, Hall CS, Scott MJ, Fuhrhop RJ, Gaffney PJ, Wickline SA, Lanza GM: Enhancement of reflectivity by specific perfluorocarbon emulsions used in site-targeted ultrasound contrast agent. Journal of Society of Photo-optical Instrumentation Engineers 2000; 1: 333-340. 81. Dent CL, Scott MJ, Wickline SA, Hall CS: High frequency ultrasound for quantitative characterization of myocardial edema. Ultrasound Med Biol 2000; 26: 375-384. 82. Hall CS, Nguyen CT, Scott MJ, Lanza GM, Wickline SA: Delineation of the extracellular determinants of ultrasonic scattering from elastic arteries. Ultrasound Med Biol 2000; 26: 613-620. 83. Lanza GM, Abendschein DR, Hall CH, Scott MJ, Scherrer DE, Houseman A, Miller JG, Wickline SA: In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. J Am Soc Echocardiogr 2000; 13: 608-614. 84. Hall CS, Dent CL, Scott MJ, Wickline SA: High-frequency ultrasound detection of the temporal evolution of protein cross-linking in myocardial tissue. IEEE Trans Ultrason Ferroelec Freq Contr 2000; 47: 1051-1058. 85. Setser R, Henson RE, Allen JS, Fischer SE, Wickline SA, Lorenz CH: Left ventricular contractility is impaired following myocardial infarction in the pig and rat: Assessment by the end systolic pressure – volume relation using a single-beat estimation technique and cine magnetic resonance imaging. Annals of Biomedical Engineering 2000; 28: 484-494. 86. Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA, 27
  28. 28. Kotyk JJ: Magnetic resonance contrast enhancement of neovascular with αvβ3-targeted nanoparticles. Magn Reson Med 2000; 44: 433-439. 87. Pohost G, Higgins CB, Grist T, Pettigrew RI, Reichek N, Wickline SA, Axel L, Manning WJ, Pennell DJ: Guidelines for credentialing in cardiovascular magnetic resonance (CMR). J Cardiovasc Magn Reson 2000; 2: 233-234. 88. Wickline SA, Fischer KC: Can infections be imaged in implanted devices? ASAIO Journal 2000; 46: S80-S81. 89. Yu X, Song S-K, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, Gaffney PJ, Wickline SA, Lanza GM: High resolution MRI characterization of human thrombus using a novel fibrin- targeted paramagnetic nanoparticle contrast agent. Magn Reson Med 2000; 44: 867-872. 90. Hall CS, Marsh JN, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM: Time evolution of enhanced ultrasonic reflection using a fibrin-targeted nanoparticle contrast agent. J Acoust Soc Am 2000; 108: 3049-3057. 91. Chia JM, Fischer SE, Wickline SA, Lorenz CH: Performance of QRS detection for cardiac magnetic resonance imaging with a novel vectorcardiographic triggering method J Magn Reson Imaging 2000; 12: 678-688. 92. Ferrara KW, Merritt CRB, Burns PN, Foster FS, Mattrey RF, Wickline SA. Evaluation of tumor angiogenesis with US: Imaging, Doppler, and contrast agents. Acad Radiol 2000; 7: 824-839. 93. Lanza G, Hall C, Scott M, Fuhrhop R, Marsh J, Wickline S: Molecular imaging with targeted ultrasound contrast agents. Proc IEEE Ultrason Symp 2000; 00CH37121: 1917- 1926. 94. Marsh JN, Hall CS, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM: Time evolution of enhanced ultrasonic reflection using a fibrin-targeted nanoparticle contrast agent. Proc IEEE Ultrason Symp 2000; 00CH37121: 1927-1930. 95. Ngo FC, Hall CS, Marsh JN, Fuhrhop RW, Allen JS, Brown P, McLean MD, Scott MJ, 28
  29. 29. Wickline SA, Lanza GM: Evaluation of liquid perfluorocarbon nanoparticles as a blood pool contrast agent utilizing power Doppler harmonic imaging. Proc IEEE Ultrason Symp 2000; 00CH3711: 1931-1934. 96. Nguyen CT, Hall CS, Scott MJ, Zhu Q, Marsh J, Wickline SA: Age-related alterations of cardiac tissue microstructure and material properties in Fischer 344 rats. Ultrasound Med Biol 2001; 27: 611-619. 97. Hall CS, Marsh JN, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM: Temperature dependence of ultrasonic enhancement with a site-targeted contrast agent. J Acoust Soc Am 2001; 110: 1677-1684. 98. Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA, Gaffney PJ, Wickline SA, Lanza GM: Novel MRI contrast agent for molecular imaging of fibrin: Implications for detecting vulnerable plaques. Circulation 2001; 104: 1280-1285. 99. Dent CL, Bowman AW, Scott MJ, Allen SJ, Lisauskas JB, Janif M, Wickline SA, Kovacs SJ: Echocardiographic characterization of fundamental mechanisms of abnormal diastolic filling in diabetic rats with a parameterized diastolic filling formalism. J Am Soc Echocardiogr 2001; 14: 1166-72. 100. Nagel E, Lorenz C, Baer F, Hundley WG, Wilke N, Neubauer S, Sechtem U, van der Wall E, Pettigrew R, de Roos A, Fleck E, van Rossum A, Pennell D, Wickline S: Stress cardiovascular magnetic resonance: Consensus panel report. J Cardiovasc Magn Reson 2001; 3: 267-281. 101. Handley SM, Ngo F, Hall C, Allen J, McLean M, Lanza G, Miller JG, Wickline SA: Age at time of infarction differentially affects the remodeling responses in viable cardiac tissue in young versus old rats. Proc IEEE Ultrason Symp 2001; 01CH37263-2: 1181-1184. 102. Hughes MS, Marsh JN, Fuhrhop RW, Chinen LK, Lanza GA, Wickline SA: Comparison of ultrasound scattering properties of Optison® with a liquid perfluorocarbon nanoparticle contrast agent. Proc IEEE Ultrason Symp 2001; 01CH37263: 1675-1678. 103. Takiuchi S, Marsh JN, Hall CS, Lanza GM, Wickline SA: Unexpected anisotropic behavior of ultrasound attenuation after collagen cross-linking in porcine tendons. Proc IEEE Ultrason Symp 2001; 01CH37263: 1253-1256. 104. Marsh JN, Hall CS, Scott MJ, Fuhrhop RJ, Gaffney PJ, Wickline SA, Lanza GM: 29
  30. 30. Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an acoustic transmission line model. IEEE Trans Ultrason Ferroelec Freq Contr 2002; 49: 29-38. 105. Wickline SA, Sahn DJ, Kerber R, Reichek N, Pennell DJ: Report from the First International Conjoint Conference on Cardiovascular Magnetic Resonance and Echocardiography. J Cardiovasc Magn Res 2002; 4: 515-520. 106. Nguyen CT, Hall CS, Wickline SA: Characterization of aortic microstructure with high- frequency ultrasound: implications for mechanisms of aortic function and dissection. IEEE Trans Ultrason Ferroelec Freq Contr 2002; 49: 1561-1571. 107. Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Chinen, LK, Fuhrhop RW, Scherrer DE, Wickline SA: Targeted antiproliferative drug delivery to vascular smooth muscle cells with magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 2002; 106: 2842-2847. 108. Lanza GM, Abendschein DR, Yu X, Winter PM, Karukstis K, Scott MJ, Fuhrhop RW, Scherrer DE, Wickline SA: Molecular imaging and targeted drug delivery with a novel, ligand-directed paramagnetic nanoparticle technology. Acad Radiol 2002; 9: S330-S331. 30
  31. 31. 109. Wickline SA, Hughes M, Ngo FC, Hall CS, Marsh JN, Brown PA, Allen JS, McLean MD, Scott MJ, Fuhrhop RW, Lanza GM: Blood contrast enhancement with a novel, non-gaseous nanoparticle contrast agent. Acad Radiol 2002; 9: S290-S293. 110. Marsh JN, Hall CS, Wickline SA, Lanza GM: Temperature dependence of acoustic impedance for specific fluorocarbon liquids. J Acoust Soc Am 2002; 112: 2858-2862. 111. Hughes MS, Marsh JN, Woodson AK, Fuhrhop RW, Lanza GM, Wickline SA: Comparison of ultrasound scattering behavior of Optison® and a liquid perflourocarbon nanoparticle contrast agent. Proceedings of IEEE Ultrason Ferroelec Freq Contr 2002; 02CH37388-2: 1965-1968. 112. Wickline SA, Lanza GM: Nanotechnology for molecular imaging and targeted therapy. Circulation 2003; 107: 1092-1095. 113. Handley SM, Ngo F, McLean M, Hall CS, Allen J, Crowder K, Miller JG, Lin SJ, Hughes MS. Wickline SA. Chronological age modifies the microscopic remodeling process in viable cardiac tissue after infarction. Ultrasound Med Biol 2003; 29(5): 659-69. 114. Winter PM, Caruthers SD, Yu X, Song SK, Chen JJ, Miller B, Bulte JWM, Robertson JD, Gaffney PJ, Wickline SA, Lanza GM. Improved Molecular Imaging Contrast Agent for Detection of Human Thrombus. Magn Reson Med 2003; 50: 411-416. 115. Chen JJ, Song SK, Liu W, McLean M, Allen JS, Tan J, Wickline SA, Yu X: Remodeling of cardiac fiber structure after infarction in rats quantified with diffusion tensor MRI. Am J Physiol Heart Circ Physiol 2003; 285: H946-H954. 116. Handley SM, Ngo F, McLean M, Hall CS, Allen J, Crowder K, Miller JG, Lin SJ, Hughes MS, Wickline SA: Chronological age modifies the microscopic remodeling process in viable cardiac tissue after infarction. Ultrasound Med Biol 2003; 29: 659-669. 117. Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang HY, Robertson JD, Wickline SA, Lanza GM: Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel α β -targeted nanoparticle and 1.5 Tesla magnetic resonance v 3 imaging. Cancer Research 2003; 63: 5838-5843. 118. Caruthers SD, Lin R, Brown P, Watkins MP, Williams TA, Lehr KA, Wickline SA: 31
  32. 32. Practical value of cardiac magnetic resonance imaging for clinical quantification of aortic valve stenosis. Comparison with echocardiography. Circulation 2003; 108: 2236-2243. 119. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS, Lacy EK, Robertson JD, Lanza GM, Wickline SA: Molecular imaging of angiogenesis in early-stage atherosclerosis with α β -integrin-targeted nanoparticles. Circulation 2003; 108: v 3 2270-2274. 120. Buxton DB, Lee SC, Wickline SA, Ferrari M: Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group. Buxton: NHLBI Nanotechnology Working Group. Circulation 2003; 108: 2737-2742. 121. Lanza GM, Wickline SA: Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr Prob Cardiology 2003; 28: 625-653. 122. Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hall CS, Marsh JN, Scott MJ, Zhang H, Schmieder A, Crowder K, Morawski A, Wickline SA: Molecular imaging and targeted drug delivery: Merging medical paradigms. Proc IEEE Ultrason Symp 2003; 03CH37476-1: 526-531. 123. Hughes MS, Marsh JN, Hall CS, Fuhrhop RW, Lanza GM, Wickline SA: Optimization of site-targeted perfluorocarbon nanoparticle contrast in whole blood for molecular imaging applications. Proc IEEE Ultrason Symp 2003; 03CH37476-1: 536-535. 124. Crowder KC, Hughes MS, Marsh JN, Scott MJ, Fuhrhop RW, Lanza GM, Wickline SA: Augmented and selective delivery of liquid perfluorocarbon nanoparticles to melanoma cells with noncavitational ultrasound. Proc IEEE Ultrason Symp 2003; 03CH37476-1: 532-535. 125. Morawski AM, Winter PM, Caruthers SD, Williams TA, Allen JS, Fuhrhop RW, Lanza GM, Wickline SA: A semi-automated algorithm for quantification of vessel wall angiogenesis associated with early atherosclerosis using magnetic resonance imaging. Proc IEEE-EMBS 2003; 03CH37439-1: 743-746. 126. Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ, Robertson JD, Abendschein DR, Lanza GM. Wickline SA: Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 2004; 51: 480-486. 32
  33. 33. 127. Rogers JH, Caruthers SD, Williams T, Lin SJ, Meyers D, Lanza GM, Kovacs S, Lasala JM, Wickline SA. Clinical utility of rapid prescreening magnetic resonance angiography of peripheral vascular disease prior to cardiac catheterization. J Cardiovasc Magn Reson 2004; 6: 25-31. 128. Wickline SA: Plaque characterization: Surrogate markers or the real thing? J Am Coll Cardiol 2004; 43: 1185-1187. 129. Marsh JN, Takiuchi S, Lin SJ, Lanza GM, Wickline SA: Ultrasonic delineation of aortic microstructure: The relative contribution of elastin and collagen to aortic elasticity. J Acoust Soc Am 2004; 115: 2032-2040. 130. Lin SJ, Brown PA, Watkins MP, Williams TA, Lehr KA, Liu W, Lanza GM, Wickline SA, Caruthers SD: Quantification of stenotic mitral valve area with magnetic resonance imaging and comparison with Doppler ultrasound. J Am Coll Cardiol 2004; 44: 133-137. 131. Liu W, Chen J, Ji S, Allen JS, Bayly PV, Wickline SA, Yu X: Harmonic phase MR tagging for direct quantification of Lagrangian strain in rat hearts after myocardial infarction. Magn Reson Med 2004; 52: 1282-1290. 132. Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, Robertson JD, Gaffney PJ, Lanza GM, Wickline SA: Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted 19F Nanoparticles. Magn Reson Med 2004; 52: 1255-1262. 133. Lanza GM, Winter PM, Caruthers SD, Morawski AM, Schmieder AH, Crowder KC, Wickline SA: Magnetic resonance molecular imaging with nanoparticles: From bench to bedside. J Nuclear Cardiol 2004; 11: 733-743. 134. Gaynor SL, Ishii Y, Diodato MD, Prasad SM, Barnett KM, Damiano NR, Byrd GD, Wickline SA, Schuessler RB, Damiano RJ: Successful performance of Cox-Maze procedure on beating heart using biopolar radiofrequency ablation: A feasibility study in animals. Ann Thorac Surg 2004; 78: 1671-1677. 135. Mokadam NA, McCarthy PM, Gillinov AM, Ryan WH, Moon MR, Mack MJ, Gaynor SL, 33
  34. 34. Prasad SM, Wickline SA, Bailey MS, Damiano NR, Ishii Y, Schuessler RB, Damiano RJ: A prospective multicenter trial of bipolar radiofrequency ablation for atrial fibrillation: Early results. Ann Thorac Surg 2004; 78: 1665-1670. 136. Lanza GM, Winter P, Caruthers S, Schmieder AH, Crowder K, Morawski A, Zhang H, Scott MJ, Wickline SA: Novel paramagnetic contrast agents for molecular imaging and targeted drug delivery. Curr Pharm Biotechnol 2004; 5: 495-507. 137. Marsh JN, Crowder KC, Hughes MS, Scott MJ, Lacy EK, Lanza GM, Wickline SA: In vitro acoustic molecular imaging of tissue factor expressed by smooth muscle cells with stable liquid perfluorocarbon nanoparticle contrast agents. IEEE Ultrason Symp 2004; 04CH37553-2: 1102-1105. 138. Hughes MS, Marsh JN, Allen J, Brown PA, Lacy EK, Scott MJ, Lanza GM, Wickline SA, Hall CS: In vivo ultrasonic detection of angiogenesis with site-targeted nanoparticle contrast agents using measure-theoretic signal receivers. IEEE Ultrason Symp 2004; 04CH37553-2: 1106-1109. 139. Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK, Zhang H, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM: Molecular MR imaging of melanoma angiogenesis with α β -Targeted paramagnetic nanoparticles. Magn Reson Med v 3 2005; 53: 621-627. 140. Hughes MS, Marsh JN, Hal CS, Savery D, Lanza GM, Wickline SA: Characterization of digital waveforms using thermodynamic analogs: Applications to detection of materials defects. IEEE Trans Ultrason Ferroelec Freq Contr 2005; 52: 1555-1564. 141. Robertson JD, Crane SB, Wickline SA, Lanza GM: Characterization and biodistribution of a novel MRI molecular imaging agent by neutron activation analysis. Journal of Radioanalytical and Nuclear Chemistry 2005; 263: 511-514. 142. Winter P, Athey P, Kiefer G, Gulyas G, Frank K, Fuhrhop R, Robertson D, Wickline S, Lanza GM: Improved paramagnetic chelate for molecular imaging with MRI. Journal of Magnetism and Magnetic Materials 2005; 293: 540-545. 143. Hughes MS, Marsh JN, Hall CS, Fuhrhop RW, Lacy EK, Lanza GM, Wickline SA: 34
  35. 35. Acoustic characterization in whole blood and plasma of site-targeted nanoparticle ultrasound contrast agent for molecular imaging. J Acoust Soc Am 2005; 117: 964-972. 144. Cyrus T, Winter PW, Caruthers SD, Wickline SA, Lanza GM: Magnetic resonance nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther 2005; 3(4): 705-715. 145. Winter PM, Shukla HP, Caruthers SD, Scott MJ, Fuhrhop RW, Robertson JD, Gaffney PJ, Wickline S, Lanza GM: Molecular imaging of human thrombus with computed tomography. Acad Radiol 2005; 12 (Suppl 1): 9-13. 146. Waters EA, Caruthers SD, Wickline SA: Correlation analysis of stenotic aortic valve flow patterns using phase contrast MRI. Ann Biomed Eng 2005; 33(7): 878-887. 147. Lanza GM, Hughes MS, Marsh JN, Scott MJ, Zhang H, Lacy EK, Allen JS, Wickline SA: Acoustic molecular imaging and targeted drug delivery with perfluorocarbon nanoparticles. AIP Conf Proc 2005; 754: 120-123. 148. Hughes MS, Marsh JN, Woodson AJ, Lacy EK, Caradine C, Lanza GM, Wickline SA: Characterization of digital waveforms using thermodynamic analogs: Detection of contrast targeted tissue in MDA 435 tumors implanted in athymic mice. Proc IEEE Ultrason Symp 2005; 05CH37716-1: 373-376. 149. Chen J, Liu W, Zhang H, Lacy L, Yang X, Song SK, Wickline SA, Yu X: Regional ventricular Wall thickening reflects changes in cardiac fiber and sheet structure during contraction: quantification with diffusion tensor MRI. Am J Physiol Heart Circ Physiol 2005; 289: H1898-1907. 150. Ashford MW, Liu W, Lin SJ, Abraszewski P, Caruthers SD, Connolly AM, Yu X, Wickline SA: Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac magnetic resonance strain imaging. Circulation 2005; 112 (16): 2462-2467. 151. Wickline SA, Lanza GM: Targeted nanoparticle beacons for quantification of molecular epitopes and drug delivery. Clinical Cancer Research 2005; 11: 9173S-9174S. 152. Crowder KC, Hughes MS, Marsh JN, Barbieri AM, Fuhrhop RW, Lanza GM, Wickline SA: sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid 35
  36. 36. delivery to cancer cells through contact-mediated mechanisms: Implications for enhanced local drug delivery. Ultrasound Med Biol 2005; 31 (12): 1693-1700. 153. Hughes MS, Marsh JN, Arbeit J, Neumann R, Fuhrhop RW, Lanza, GM, Wickline SA.: Ultrasonic molecular imaging of primordial angiogenic vessels in rabbit and mouse models with avb3-integrin targeted nanoparticles using information-theoretic signal detection: Results at high frequency and in the clinical diagnostic frequency range. Proc IEEE Ultrason Symp 2005; 05CH37716-1: 617-620. 154. Marsh JN, Pan A, Hu G, Crowder KC, Scott MJ, Hughes MS, Wickline SA, Lanza GM: Fibrin-targeted thrombolytic therapy using acoustically reflective perfluorocarbon nanoparticles. Proc IEEE Ultrason Symp 2005; 05CH37716-2: 992-995. 155. Soman NR, Marsh JN, Hughes MS, Lanza GM, Wickline SA: Noncavitational mechanisms of interaction of targeted perfluorocarbon nanoparticles: Implications for drug delivery. Proc IEEE Ultrason Symp 2005; 05CH37716-3: 1712-1715. 156. Cyrus T, Abendschein DR, Caruthers SD, Harris TD, Glattauer V, Werkmeister JA, Ramshaw JA, Wickline SA, Lanza, G.M: MR three-dimensional molecular imaging of intramural biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson 2006; 8: 535-541. 157. Caruthers SD, Neubauer AM, Hockett FD, Lamerichs R, Winter PM, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM. In vitro demonstration using 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol 2006; 41: 305-312. 158. Chung J, Abraszewski P, Yu X, Liu W, Krainik A, Ashford M, Caruthers SD, McGill JB, Wickline SA: Paradoxical increase in ventricular torsion and systolic torsion rate in Type I diabetic patients under tight glycemic control. J Am Coll Cardiol 2006; 47: 384-390. 159. Soman NR, Marsh, JN, Hughes MS, Lanza GM, Wickline SA: Acoustic activation of targeted liquid perfluorocarbon nanoparticles does not compromise endothelial integrity. IEEE Trans NanoBioscience 2006; 5: 69-75. 160. Winter PM, Caruthers SD, Wickline SA, Lanza GM: Molecular imaging by MRI. Curr Cardiol Rep 2006; 8: 65-69. 161. Wickline SA, Lanza GM: Nanotechnology for molecular imaging and targeted drug delivery. 36
  37. 37. Annals of Oncology 2006; 17: 30. 162. Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G: Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 2006; 26: 435-441. 163. Hughes M, Marsh JN, Zhang H, Woodson AK, Allen JS, Lacy EK, Caradine C, Lanza GM, Wickline SA: Characterization of digital waveforms using thermodynamic analogs: Detection of contrast-targeted tissue in vivo. IEEE Trans Ultrason Ferroelectr Freq Contr 2006; 53: 1609-1616. 164. Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM: Endothelial avb3 integrin- targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 2103-2109. 165. Liu W, Ashford MW, Chen J, Watkins MP, Williams TA, Wickline SA, Yu X: MR tagging demonstrates quantitative differences in regional ventricular wall motion in mice, rats, and men. Am J Physiol Heart Circ Physiol 2006; 291: H2515-2521. 166. Winter PM, Cai K, Chen J, Adair CR, Kiefer GE, Athey PS, Gaffney PJ, Buff CE, Robertson JD, Caruthers SD, Wickline SA, Lanza GM: Targeted PARACEST nanoparticle contrast agent for the detection of fibrin. Magn Reson Med 2006; 56: 1384-1388. 167. Lanza GM, Winter P, Cyrus T, Caruthers S, Marsh J, Hughes M, Wickline S: Nanomedicine opportunities in cardiology. Ann N Y Acad Sci 2006; 1080: 451-465. 168. Lanza GM, Winter PM, Caruthers SD, Hughes MS, Cyrus T, Marsh JN, Neubauer AM, Partlow KC, Wickline SA: Nanomedicine opportunities for cardiovascular disease with perfluorocarbon nanoparticles. Nanomedicine 2006; 1: 321-329. 169. Caruthers SD, Wickline SA, Lanza GM: Nanotechnological applications in medicine. Curr Opin Biotechnol 2007; 18: 26-30. 170. Neubauer AM, Caruthers SD, Hockett FD, Cyrus T, Robertson JD, Allen JS, Williams TD, 37
  38. 38. Fuhrhop RW, Lanza GM, Wickline SA: Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. J Cardiovasc Magn Reson 2007; 9: 565-573. 171. Hu G, Lijowski M, Zhang H, Partlow KC, Caruthers SD, Kiefer G, Gulyas G, Athey P, Scott MJ, Wickline SA, Lanza GM: Imaging of Vx-2 rabbit tumors with alpha(nu)beta(3)-integrin targeted 111In nanoparticles. Int J Cancer 2007; 120: 1951-1957. 172. Marsh JN, Partlow KC, Abendschein DR, Scott MJ, Lanza GM, Wickline SA: Molecular imaging with targeted perfluorocarbon nanoparticles: Quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med Biol 2007; 33: 950-958. 38
  39. 39. 173. Hughes MS, Marsh JN, Wallace KD, Donahue TA, Connolly AM, Lanza GM, Wickline SA: Sensitive ultrasonic detection of dystrophic skeletal muscle in patients with Duchenne muscular dystrophy using an entropy-based signal receiver. Ultrasound Med Biol 2007; 33: 1236-1243. 174. Hughes MS, McCarthy JE, Marsh JN, Arbeit JM, Neumann RG, Fuhrhop RW, Wallace KD, Znidersic DR, Maurizi BN, Baldwin SL, Lanza GM, Wickline SA: Properties of an Entropy- based Signal Receiver with an Application to Ultrasonic Molecular Imaging. J Acous Soc Am 2007; 121: 3542-3557. 175. Partlow KC, Chen J, Brant JA, Neubauer AM, Meyerrose TE, Creer MH, Nolta JA, Caruthers SD, Lanza GM, Wickline SA: 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007; 21: 1647-1654. 176. Marsh JN, Senpan A, Hu G, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM: Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine 2007; 2: 533-543. 177. Ripplinger CM, Li W, Hadley J, Chen J, Rothenberg F, Lombardi R, Wickline SA, Marian AJ, Efimov IR: Enhanced transmural fiber rotation and connexin 43 heterogeneity are associated with an increased upper limit of vulnerability in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res 2007; 101: 1049-1057. 178. Wallace KD, Marsh JN, Baldwin SL, Connolly AM, Keeling R, Lanza GM, Wickline SA, Hughes MS: Sensitive Ultrasonic Delineation of Steroid Treatment in Living Dystrophic Mice with Energy-based and Entropy-based Radio Frequency Signal Processing. IEEE Trans Ultrason Ferroelectr Freq Control 2007; 54: 2291-2299. 179. Tran TD, Caruthers SD, Hughes M, Cyrus T, Winter PM, Morawski AN, Wickline SA, Lanza GM: Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Int J Nanomedicine 2007; 2: 515-526. 180. Cyrus T, Allen JS, Williams TA, Fuhrhop RW, Harris TD, Glattauer V, Werkmeister J, Ramshaw J, Wickline SA, Lanza GM: Intramural delivery of rapamycin with avb3-integrin- targeted paramagnetic nanoparticles inhibits stenosis following angioplasty. Arterioscler Thromb Vasc Biol (In press) 181. Hughes M, Caruthers S, Tran T, Marsh J, Wallace K, Cyrus T, Partlow KP, Scott M, Lijowski M, Neubauer A, Winter P, Hu G, Zhang H, McCarthy J, Maurizi B, Allen J, Caradine C, 39
  40. 40. Neumann R, Arbeit J, Lanza G, Wickline S: Perfluorocarbon nanoparticles for molecular imaging and targeted therapeutics. Proceedings of the IEEE 2008; 96: _____ (In press) 182. Chen J, Wang Q, Zhang H, Yang X, Wang J, Berkowitz BA, Wickline SA, Song SK: In vivo quantification of T1, T2, and appartent diffusion coefficient in the mouse retina at 11.74. Magn Res Med (Accepted) 183. Soman N, Marsh J, Hughes M, Lanza G, Wickline S: New mechanisms for nonporative ultrasound stimulation of cargo delivery to cell cytosol with targeted perfluorocarbon nanoparticles. Nanotechnology (Accepted) 184. Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams T, Allen JS, Harris TD, Wickline SA, Lanza GM. Antiangiogenic therapy of early-stage atherosclerosis with avb3-integrin-targeted fumagillin nanoparticles. ATVB (In review) 185. Partlow KC, Lanza GM, Wickline SA: Lipid-drug delivery from molecularly targeted nanoparticles utilizes caveolar lipid raft transport mechanisms. FASEB J (In review) 186. Waters EA, Chen J, Allen JS, Lanza GM, Wickline SA: Detection and quantification of angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine MRI/MRS. J Cardiovasc Magn Reson (In review) 187. Neubauer M, Caruthers SD, Hockett FD, Winter PM, Chen J, Gaffney PJ, Robertson JD, Lanza GM, Wickline SA: Tunable perfluorocarbon nanoparticles for molecular imaging using gadolinium-modulated 19F signals. Magn Res Med (In review) 188. Partlow KC, Brant JA, Marsh JN, Creer MH, Nolta JA, Hughes MS, Lanza GM, Wickline SA: Extraordinary acceleration of endocytosis with acoustic energy: Mechanisms and practical applications. Nature Biotechnology (In review) 189. Partlow KC, Lanza GM, Wickline SA: Exploiting lipid raft transport with targeted nanoparticles: A strategy for cytosolic drug delivery. Biomaterials (In review) 190. Neubauer AM, Caruthers SD, Brant J, Partlow KC, Lanza GM, Wickline SA: 19F MRI at 3.0 T: Sensitivity and detection limits for molecular imaging and cell labeling. Magn Res Med (In review) 40
  41. 41. 191. Myerson JW, Chen J, Yang X, Neubauer AM, Lanza GM, Wickline SA: A novel real time approach for in vivo pharmacokinetic modeling of perfluorocarbon nanoparticles employing quantitative 19F magnetic resonance spectroscopy. Magn Res Med (In revision) 192. Neubauer AM, Sim H, Winter PW, Caruthers SD, Williams TA, Robertson JD, Sept D, Lanza GM, Wickline SA: Novel nanoparticle pharmacokinetic profiling based on in vivo magnetic resonance imaging. J Magn Res Imaging (In review) 193. Chen J, Waters EA, Yang X, Zhang H, Neumann R, Arbeit J, Lanza GM, Wickline SA: Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR specroscopy. J Magn Res Imaging (In review) 194. Southworth R, Kaneda M, Chen J, Zhang L, Zhang H, Yang X, Razavi R, Lanza G, Wickline S: Renal vascular inflammation induced by western diet in ApoE-null mice quantified by 19F NMR of VCAM-1 targeted nanobeacons. Circ Res (In review) 195. Soman NR, Lanza GM, Wickline SA, Schlesinger PH: Targeting cytotoxic cell penetrating peptides (Melittin) with self-assembling nanoemulsions. Cell (In review) 196. Soman NR, Lanza GM, Wickline SA, Schlesinger PH: Synthesis and characterization of perfluorocarbon nanodroplets as drug delivery vehicles for cytolytic peptides. Nanoletters (In review) 197. Kaneda M, Lanza GM, Milbrant J, Wickline SA: siRNA delivery with PFC nanoparticles: Downregulation of vascular adhesion molecules (In preparation) Invited Publications/Book Chapters/Reviews 1. Soeter JR, Wickline SA, McNamara JJ: Carotid and aortic root perfusion during venoarterial bypass in primates. In: Artificial Lungs for Acute Respiratory Failure. Warren Zapol and Jasper Quist, editors. Academic Press, NY. Hemisphere Publishing Corp., Washington, D.C., 1976, pp 275-81. 2. Fields LE, Wickline SA: Hypertension. Chapter 4 in: Manual of Medical Therapeutics (25th edition). Department of Medicine, Washington University School of Medicine, St. Louis, Missouri. Matthew Orland, M.D. and Robert Saltman, M.D., editors. Little, Brown and Company, Boston, 1986. 41
  42. 42. 3. Perez JE, Miller JG, Barzilai B, Wickline SA, Mohr GA, Wear K, Vered Z, Sobel BE: Progress in quantitative ultrasonic characterization of myocardium: from the laboratory to the bedside. J Am Society of Echocardiography 4: 294, 1988. 4. Perez JE, Barzilai B, Wickline SA, Vered Z, Sobel BE, Miller JG: Quantitative characterization of myocardium with ultrasonic imaging. J Nuc Med Allied Sci 32: 149, 1988. 5. Wickline SA, Perez JE, Mohr GA, Wear KA, Milunski MR, Barzilai B, Sobel BE, Miller JG: Ultrasonic characterization of cardiovascular tissue. In: Proceedings of NIH Conference on Modeling in Biomedical Research: An Assessment of Current and Potential Approaches, Applications to Studies in Cardiovascular/Pulmonary Function and Diabetes. May 1-3, 1989. 6. Perez JE, Wickline SA, Barzilai B, Loomis JS, Waggoner A, Miller JG: Ultrasonic integrated backscatter imaging. Dynamic Cardiovascular Imaging 2: 87-91, 1989. 7. Miller JG, Barzilai B, Milunski MR, Mohr GA, Perez JE, Wear KA, Wickline SA, Vered Z, Sobel BE: Myocardial tissue characterization: Clinical confirmation of laboratory results. IEEE Ultrason Symp 89CH2791-2: 1029-36, 1989. 8. Wickline SA, Sobel BE: Ultrasonic tissue characterization: Prospects for clinical investigation. J Am Coll Cardiol 14: 1709, 1989. 9. Perez JE, Miller JG, Wickline SA, Milunski MR, Barzilai B, Sobel BE: Myocardial tissue characterization. Progress in Cardiology 3(1): 83-96, 1990. 10. Perez JE, Miller JG, Wickline SA, Barzilai B, Sobel BE: Assessment of myocardial viability with analysis of ultrasonic integrated backscatter. Proc 12th International Conference of IEEE Engineering Med Biol Society 12: 325-326, 1990. 11. Skorton DJ, Miller JG, Wickline SA, Barzilai B, Collins SM, Perez JE: Ultrasonic characterization of cardiac tissue. Chapter 26 in: Cardiac Imaging-Principles and Practice. Marcus ML, Schelbert HR, Skorton DJ, Wolf G, editors. WB Saunders, Co., Philadelphia PA. 1991, 538-556. 12. Wickline SA, Perez JE, Miller JG: Chapter 10: Cardiovascular tissue characterization in vivo, in: Shung KK and GA Thieme (ed). Ultrasonic Scattering In Biological Tissues. Boca Raton, FL, CRC Press, 1993, 313-345. 42
  43. 43. 13. Perez, JE, Miller JG, Holland MR, Wickline SA, Waggoner AD, Barzilai B, Sobel BE: Ultrasonic tissue characterization: Integrated backscatter imaging for detecting myocardial structural properties and on-line quantification of cardiac function. Am J Cardiac Imaging 8: 106-112, 1994. 14. Wickline SA: Quantitative Ultrasonic Imaging. Chapter 23 in Vascular Surgery: Theory and Practice. Callow AD & CB Ernest, editors. Appleton & Lange, Stamford, CT. 1995, 331-334. 15. Lanza GM, Wallace KD, Miller JG, Wickline SA: Development of a Novel Site Targeted Ultrasonic Contrast Agent. In: Advances in Echo Imaging Using Contrast Enhancement. Nanda NC, Schlief R, Goldberg BB, editors. Kluwer Academic Publishers, Norwell, MA. 1997, 655-667. 16. Wickline SA, Miller JG, Lanza G: Quantitative ultrasonic tissue characterization with intravascular and transcutaneous ultrasound. In: Non-invasive Imaging of Atherosclerosis. M. Mercuri, D.D. McPherson, H. Bassiouny, S. Glagov, editors. Kluwer Academic Publishers, Norwell, MA. 1998, 169-188. 17. Wickline S, Wu K, Didisheim P, Anderson JM, Budinger TF, Fuster V, Harker LA, Kottke-Marchant K, Maki DG, Strauss W, Callahan TH, Watson JT, Berson A: NHLBI/FDA conference on thrombosis and infections with cardiovascular devices. J Biomed Mater Res 42: 341-346, 1998. 18. Holland MR, Perez JE, Wickline SA, Handley SM, Finch-Johnston AE, Mobley J, Hall CS, Wallace KD, Miller JG: Clinical implementation of ultrasonic quantitative nondestructive evaluation of the heart: A review. Nondestr Test Eval 14: 217-235, 1998. 43
  44. 44. 19. Nagel E, Underwood R, Pennell D, Sechtem UP, Neubauer S, Wickline S, Hes OM, Schwaiger M, Fleck E: Recent developments in non-invasive heart imaging. Critical evaluation of the use of cardiac magnetic resonance tomography – results of an interdisciplinary workshop. Dtsch Med Wochenschr 123: 1018-1021, 1998. 20. Budinger TF, Berson A, McVeigh ER, Pettigrew RI, Pohost GM, Watson JT, Wickline SA: Cardiac MR imaging: Report of a working group sponsored by the National Heart, Lung, and Blood Institute. Radiology 208: 573-576, 1998. 21. Miller JG, Perez JE, Wickline SA, Baldwin SL, Barzilai B, Davila-Roman V, Fedewa RJ, Finch-Johnston AE, Hall CS, Handley SM, Hockett FD, Holland MR, Kovacs A, Lanza GM, Lewis SS, Marsh JN, Mobley J, Sosnovik DE, Trousil RL, Wallace KD, Waters KR: Backscatter Imaging and myocardial tissue characterization. Proc IEEE Ultrason Symp 98CH36102: 1373-1379, 1998. 22. Budinger T, Berson A, McVeigh E, Pettigrew R, Pohost G, Watson J, Wickline S: NHLBI Working Group on Cardiovascular Magnetic Resonance: Magnetic Resonance Imaging of the Cardiovascular System. J Cardiovasc Magn Reson 1: 53-58, 1999. 23. Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and therapy. In: Progress in Cardiovascular Diseases. M. Lesch and E.H. Sonneblick, editors. W.B. Saunders, Philadelphia, PA. 2000, 13-31. 24. Holland MR, Wickline SA: Ultrasonic Characterization of Myocardium. In: Interstitial Fibrosis in Heart Failure. F. Villa real, editor. Kluwer Academic Publishers, Norwell, MA. 25. Wickline SA, Lanza GM: Molecular imaging, targeted therapeutics, and nanoscience. J Cellular Biochemistry 87 (Suppl 39): 90-97, 2002. 26. Lanza GM, Lamerichs R, Caruthers S, Wickline SA: Molecular imaging in MR with a targeted paramagnetic nanoparticles. Medica Mundi 47: 34-39, 2003. 27. Hughes MS, Lanza GM, Marsh JN, Wickline SA: Targeted Ultrasonic Contrast Agents for Molecular Imaging and Therapy: A Brief Review. Medica Mundi 47: 66-73, 2003. 28. Lanza GM, Caruthers SD, Wickline SA: Molecular Imaging. In: Cardiovascular Magnetic Resonance, ed Lardo, Fayad, Chronos and Fuster. Taylor and Francis Group 2004; 501-516. 29. Morawski AM, Lanza GM, Wickline SA. Targeted contrast agents for magnetic resonance 44
  45. 45. imaging and ultrasound. Curr Opin Biotechnol 2005; 16: 89-92. 30. Lanza GM, Winter PM, Neubauer AM, Caruthers SD, Hockett F, Wickline SA: 1H/19F magnetic resonance molecular imaging with perfluorocarbon nanoparticles. In: Current Topics in Developmental Biology: In Vivo Cellular and Molecular Imaging. Eric T. Ahrens, editor. 2005; 70: 57-76. 31. Winter PM, Caruthers SD, Wickline SA, Lanza GM: Nanotechnologies for cellular and molecular imaging by MRI: Techniques, Tools, Applications, and Impact. In: Nanofabrication Towards Biomedical Applications. CSSR Kumar, J Hormes, C Leuschner (Eds.) Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, 2005; 227-249. 32. Caruthers S, Winter P, Wickline SA, Lanza GM. "Targeted Magnetic Resonance Imaging Contrast Agents”. In: Magnetic Resonance Imaging: Methods Mol Med 2006; 124: 387-400. 33. Lanza GM, Winter PM, Hughes MS, Caruthers SD, Marsh JN, Morawski AM, Schmieder AH, Scott MJ, Fuhrhop RW, Zhang H, Hu G, Lacy EK, Allen JS, Wickline SA. Molecular imaging and therapy: New paradigms for 21st century medicine. In: Polymeric Drug Delivery I: Particulate Drug Carriers. Sonke Svenson, editor. American Chemical Society Symposium Series 2006; 923: 295-311. 34. Caruthers SD, Wickline SA, Lanza GM: Targeted Nanoparticles for Molecular Imaging and Therapy. Chapter 19. In: Advances in Healthcare Technology: Shaping the Future of Medical Care. Gerhard Spekowius, Thomas Wendler Editors. Springer, 2006, 305-322. 35. Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM: Nanoparticles for magnetic resonance imaging of tumors. In: Nanomaterials for Cancer Therapy and Diagnosis (Series: Nanotechnologies for Life Sciences, Volume 6). Editor: Challa S.S.R. Kumar. Wiley-VCH Verlag GmbH, 2007; 121-146. 36. Winter PM, Cai K, Caruthers SD, Wickline SA, Lanza GM: Emerging nanomedcine opportunities with perfluorocarbon nanoparticles. Expert Rev Med Devices 2007; 4: 137-145. 37. Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM: Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007; 25: 667-680. 45
  46. 46. 38. Neubauer AM, Winter P, Caruthers S, Lanza GM, Wickline SA: Magnetic resonance molecular imaging and targeted therapeutics. In: Contemporary Cardiology: Cardiovascular magnetic resonance imaging. Kwong RY, ed. Humana Press; 2007; 639-662. 39. Cyrus T, Lanza GM, Wickline SA: Molecular Imaging by Cardiovascular MR. J Cardiovasc Magn Reson 2007; 9: 827-843. 40. Lanza GM, Winter PM, Neubauer AM, Crowder KC, Caruthers SD, Wickline SA: Atherosclerosis imaging with nanoparticles. In: Cardiovascular Molecular Imaging. Sinusas and Groppler (In press) 41. Lanza GM, Winter PM, Caruthers SD, Cyrus T, Yu X, Abendschein DR, Werkmeister J, Ramshaw J, Wickline SA. Targeted drug delivery with novel paramagnetic nanoparticles: Implications for MR interventional cardiology. Cardiovascular Reviews and Reports (In press) 46

×